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Abstract   
 
Aims Randomised controlled trials have reported an association between pioglitazone and 
reduced incidence of stroke in type 2 diabetic (T2DM) and insulin-resistant populations. We 
investigated this association within a real-world database. 
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Materials and methods T2DM patients initiating pioglitazone between 2000-2012 were 
extracted from the Clinical Practice Research Datalink (CPRD); a UK routine. Two non-
exposed control cohorts were matched on age, gender, HbA1c, diabetes duration, stroke 
history, co-morbidities and prior T2DM regimen. Control cohort-1 comprised patients 
initiating a new T2DM therapy as their respective case initiated pioglitazone.  Control cohort-
2 remained on the same T2DM regimen as their respective case prior to the case initiating 
pioglitazone. The primary outcome was incident stroke; other outcomes included mortality, 
hospital length of stay and stroke recurrence.  
Results 4,234 pioglitazone patients matched to controls in cohort-1 and 3,604 in cohort-2.  
For the primary outcome there were significantly reduced hazard ratios (HRs) for 
cases:controls. Cohort 1, the HR was 0.627 (95% CI, 0.404-0.972) during the therapy period 
and 0.640 (0.485-0.843) over the entire observation period; respective HRs were 0.516 
(0.336-0.794) and 0.773 (0.611-0.978) for cohort 2.  There was no significant difference in 
30-day mortality rate or rate of recurrent stroke. For hospitalised stroke events there was a 
significant difference in length of stay for patients discharged to usual residence (median 3.0 
days versus 7.0 days; p=0.008) for control cohort-2 whilst on-treatment. 
Conclusions In support of evidence from two large randomized trials, these observational 
data show that pioglitazone has a potent effect in reducing stroke events in patients with type 
2 diabetes.  
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Introduction 
 
Type 2 diabetes in an increasing public health concern with an estimated prevalence of 4.5% 
in the United Kingdom
1
 and approximately 8.0% in the United States.
2
 Type 2 diabetes is 
known to increase the risk of stroke relative to the non-diabetic population.
3,4
 Insulin 
resistance, which is a predictor of the future development of type 2 diabetes, also appears to 
be a strong stroke risk factor. This metabolic state is reported in approximately half of all 
stroke patients without diabetes.
5
 The treatment of insulin resistance in those at high risk of 
stroke, regardless of diabetes status, could therefore offer potential benefit for high-risk 
patients.
6
 
Glucose-lowering drugs of the thiazolidinedione (TZD) class increase peripheral sensitivity 
to insulin, thereby reducing insulin resistance and hyperinsulinemia.
7
 The TZD pioglitazone 
has properties that may improve other risk factors associated with cerebrovascular disease, 
such as dyslipidaemia,
8
 blood pressure,
9
 and inflammation. The drug may also have direct 
anti-atherosclerotic effects via PPAR-γ, the nuclear transcription factor activated by this class 
of drugs.  In the PROspective pioglitAzone Clinical Trial In macroVascular Events 
(PROactive) study, pioglitazone therapy was associated with a markedly reduced incidence 
of stroke in patients with type 2 diabetes and prior stroke.
10,11
 Recent data on insulin-
resistant, but non-diabetic patients with a prior history of stroke or transient ischemic attack 
(TIA) from the Insulin Resistance Intervention after Stroke (IRIS) trial
12,13,14
 also indicate a 
benefit in reducing recurrent stroke and myocardial infarction. 
Whilst prospective randomised trials may be considered a gold standard that allow for the 
equalisation of differences between groups, the inclusion/exclusion criteria applied can 
reduce the study population to a non-representative sub-set of those that will receive the 
therapy in real-life clinical practice. The aim of this study therefore is to determine whether 
the reduced incidence of stroke associated with pioglitazone is observed within a 
retrospective UK database derived from day-to-day primary care practice. 
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Methods 
 
Data source 
The study was conducted using data from the Clinical Practice Research Datalink (CPRD)
15
. 
The core dataset within CPRD is CPRD GOLD which comprises anonymised, longitudinal 
data from approximately 700 primary care practices from the United Kingdom. Available 
data includes patient demographics, diagnoses, prescription history for prescriptions 
emanating in primary care and laboratory test results. For a sub-cohort of those primary care 
practices based in England, linkage to other data sources has been undertaken. The linked 
data sources used within this study were the Health Episodes Statistics (HES);
16
 providing 
details of inpatient hospital contacts, and Office of National Statistics (ONS)
17
 mortality 
dataset.  
 
Patient selection 
Patients eligible for linkage to HES and ONS, and of acceptable research quality as defined 
by CPRD, were selected for this study. Patients with type 2 diabetes were identified by 
previously used algorithms
18
 that select patients based on diagnostic codes and treatment 
history. A wash-in period of at least 90 days from the later of the patient’s registration date 
and the practice’s up-to-standard date to the patient’s first recorded diagnosis of diabetes was 
required to allow selection from an approximate type 2 diabetes incident population.  
From this pool of patients, those initiating pioglitazone between 1
st
 January 2000 and 31
st
 
December 2012 were selected. Patients with a prior history of heart failure were excluded 
since the drug is contraindicated in this group. Date of first prescription for pioglitazone was 
defined as the case index date. The duration of treatment was defined as from index date to 
the date of the last prescription in the regimen, (that is prior to change of any regimen 
component) augmented by the estimated duration of that prescription. If the duration could 
not be calculated a default value of 28 days was used. 
Pioglitazone exposed patients were matched to two cohorts controls at ratios of 1:1. The pool 
of control patients comprised those with an incident diagnosis of type 2 diabetes, no history 
of heart failure, and no history of receiving a TZD at any point in their patient record.  
The first control cohort was comprised of those individuals on the same previous glucose-
lowering regimen as their respective case and who changed to a different (i.e., non-TZD) 
glucose-lowering therapy within 180 days of the case index date. The index date for the 
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controls was defined as the date of medication change.  The second control cohort included 
those who remained on the same glucose-lowering regimen as their respective case prior to 
the case initiating pioglitazone. The index date for these controls was defined as the date of 
the controls initiation with that therapy plus the duration on the regimen of their respective 
case prior to the addition of pioglitazone. 
For both control cohorts the following matching criteria was used: age (+/- 3 years), gender, 
HbA1c (+/- 1%), duration of diagnosed diabetes (+/- 1 year), history of stroke prior to index 
date, Charlson co-morbidity index matching on scores of 1, 2 or 3+, and same glucose-
lowering drug class combination immediately prior to index date. 
 
Outcomes 
The primary outcome was time to first stroke post index date. Incident stroke events were 
defined by Read code within the CPRD GOLD database or ICD-10 code in either the HES or 
ONS datasets.  
Secondary outcomes were: 
• the proportion of first stroke events that resulted in death within 28 days (fatal stroke). 
• the inpatient length of stay following hospital admission for stroke 
• recurrence of stroke 
 
Statistical analysis 
Baseline characteristics were compared using the chi-squared test for categorical variables 
and t-test for continuous variables. All analyses were performed twice; firstly with follow-up 
restricted to on-treatment, that is the time the patient remained on the index regimen defined 
as date of last prescription + 90 days and secondly for the entire follow-up period within the 
database. 
For the primary outcome, time to first stroke was evaluated using the Cox proportional 
hazards model (CPHM). Hazard ratios (HRs) were calculated with 95% confidence intervals 
and adjusted for age, sex, body mass index (BMI), duration of diabetes, systolic blood 
pressure, HbA1c, total cholesterol, lipid-lowering therapy, antihypertensive therapy, 
antiplatelet therapy, Charlson comorbidity index, the number of primary care contacts in the 
year prior to index date, smoking status, prior history of atrial fibrillation and prior history of 
stroke. For BMI, total cholesterol and systolic blood pressure values observed in the 30 days 
prior to index date were used. If no readings were available in this time-frame, values in the 
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30 days subsequent to index date were used. If values were still missing then the nearest 
value to the index date within the preceding 365 days was used. 
The proportion of stroke events resulting in 28-day death was compared between treatment 
groups using a logistic regression model adjusting for age, gender and Charlson index. The 
Mann-Whitney U test was used to compare the length of stay in hospital following stroke. 
Logistic regression was used to investigate the likelihood of discharge to usual place of 
residence. 
 
Studies using CPRD are covered by ethics approval granted by Trent Multicentre Research 
Ethics Committee (Reference 05/MRE04/87). CPRD Independent Scientific Advisory 
Committee approval was granted for this study (ISAC 16-292). CPRD studies which do  
not include patient identifiable data do not require patient consent. Patients are able to opt-out 
of CPRD; such that their data is not extracted from their particular primary care practice.  
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Results 
 
Identified patients and baseline characteristics 
7,577 patients initiated with pioglitazone met the initial study inclusion criteria. Of these 
pioglitazone patients, 4,234 (55.9%) could be matched at a ratio of 1:1 to the first control 
cohort and 3,604 (47.6%) could be matched to the second. Baseline characteristics for each 
matched cohort are shown in Tables 1 and 2, respectively. Compared with control cohort-1, 
cases had significantly higher BMI (32.2 versus 31.7 kg/m
2
), were more likely to have 
received lipid lowering therapy (81.7% versus 77.8%) and less likely to have a history of 
atrial fibrillation in their patient record (3.4% versus 4.4%). The most common index 
regimen for cases was metformin and pioglitazone (49.3%) and for controls was metformin 
and sulfonylurea (43.9%) (supplementary tables 1 and 2). 
 
Compared with control cohort-2, cases had a greater number of primary care contacts in the 
12 months prior to index date (10.4 versus 9.6), a significantly higher mean BMI (32.3 versus 
31.6 kg/m
2
), lower cholesterol (4.3 versus 4.5 mmol/l) and more likely to receive lipid 
lowering (82.7% versus 75.0%), anti-hypertensive (72.7% versus 69.4%), and anti-platelet 
therapies (45.5% versus 41.1%). The most common index regimen for cases was metformin 
and pioglitazone (52.0%) and for controls was metformin and sulfonylurea (33.5%) 
(supplementary tables 1 and 2) 
 
Primary outcome. 
In comparison with control cohort-1, the rate of stroke events whilst on-treatment was 5.0 per 
1,000 person years (kpy) exposure for cases (pioglitazone) versus 7.5 per kpy for controls; a 
crude relative risk of 0.662 (0.462-0.952), Table 3. After adjusting for co-variates in the 
CPHM, the hazard ratio (HR) was 0.666 (0.466-0.952, Figure 1). Over the duration of the 
entire follow-up period, the crude event rate was 7.5 versus 9.9 events per kpy exposure; a 
crude relative risk of 0.761 (0.622-0.930) and HR of 0.750 (0.612-0.919). 
In comparison with control cohort-2 the crude event rates on-treatment were 3.9 versus 7.0 
events per kpy exposure, respectively, a crude relative risk of 0.551 (0.362-0.827). The 
adjusted hazard ratio was 0.516 (0.336-0.794) (Figure 1). For the analysis that followed 
patients for the entire follow-up period, the respective rates were 7.2 versus 8.5 events per 
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kpy exposure (crude relative rate 0.844, 0.672-1.060, Table 3). The HR was 0.773 (0.611-
0.978) (Figure 1). 
Supplementary table 3 reports the hazard ratios for patient with and without prior history of 
stroke. 
 
Secondary outcomes 
Stroke recurrence and mortality 
There was no difference between cases and controls in the 30-day mortality rate following 
the index stroke event. For events observed during the on-treatment period, the proportion of 
deaths was 12.0% versus 12.7% (p=0.444) for control cohort-1 and 8.8% versus 10.1% 
(p=0.358) for control cohort-2. Following patients until the end of the observed period, the 
respective figures were 10.3% versus 12.3% (p=0.121) and 11.1% versus 11.8% (p=0.832); 
(Table 4). 
There was also no significant difference in the rate of recurrent strokes in each control cohort 
over either follow-up period. For control cohort-1, the HR was 0.558 (0.104-2.978) for 
patients during the therapy period and 0.921(0.504-1.683) over the entire observed period. 
For control cohort-2 the respective figures were 0.298 (0.033-2.679) and 0.761(0.399-1.451) 
(Supplementary table 4). 
Hospital outcomes 
For those incident stroke events resulting in hospital admission, there was no significant 
difference in overall length of stay for control cohort 1 over either the on-treatment follow-up 
period (4.0 days versus 5.0; p=0.419) or over the entire follow-up period (7.0 versus 6.0; 
p=0.417). There was also no significant difference when considering those admissions that 
resulted in discharge to the patient’s usual place of residence: 3.0 days versus 3.0 (p=0.645) 
and 6.0 versus 3.0 (p=0.196), respectively (Table 5).  
For cohort 2, however, there was a significant difference in length of stay for the incident 
stroke admission during the on-treatment period (3.0 days versus 8.0; p=0.002) but no 
significant difference over the entire follow-up period (6.0 days versus 7.0; p=0.941). For 
those admissions resulting in discharge to the patient’s usual place of residence, there was a 
significant difference for those events occurring during the therapy period (3.0 versus 7.0; 
p=0.008). For the entire follow-up period, there was no significant difference, however (5.0 
versus 6.0 days p=0.485), (Table 5). 
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Discussion 
In this study, we have shown a significantly reduced risk of incident stroke in patients treated 
with pioglitazone compared with matched controls using other glucose lowering agents for 
T2DM. This was observed for both control sets and over both follow-up periods. 
Interestingly, the hazard ratios were lower during the period on-treatment compared with 
over the entire follow-up period in both control sets. If the association we find is related 
causally to pioglitazone treatment, this observation suggests attenuation of treatment effect 
over time, as suggested in long-term follow-up of the original PROactive cohort.
14
 
There was no difference in the secondary outcomes of proportion of incident strokes resulting 
in death or time to recurrent stroke between cases and controls in either control cohort or over 
either follow-up period. In each however, the odds ratio was below unity with wide 
confidence limits, likely due to small numbers.  For strokes resulting in hospitalisation there 
was no significant difference in length of stay overall or for patients discharged to their usual 
place of residence for patients in control set 1 over either the on-treatment or entire follow-up 
periods. For those patients in control set 2, length of stay was significantly lower for 
pioglitazone patients whilst on-treatment overall (median 3.0 versus 8.0 days) and for 
admissions resulting in discharge to the patient’s usual residence (median 3.0 versus 7.0 
days). There was no significant difference over the entire follow-up period, however.  
For the primary outcome, the adjusted hazard ratios we observed on-treatment (HR = 0.627 
(0.404-0.972) and 0.516 (0.336-0.794) for cohorts 1 and 2 respectively)  were more 
favourable to pioglitazone  than those observed for the overall stroke outcome in the 
PROactive trial (0.81 [0.61-1.07]) although there was considerable overlap of the 95% 
confidence intervals.
11
 In a sub-analysis comparing patients enrolled with prior stroke, the 
PROactive investigators reported a hazard ratio for stroke of 0.53 (0.34–0.85). It should be 
noted that that trial was conducted in a population (N=5,238) with pre-existing macrovascular 
disease, whereas this was not an inclusion criteria in our study.  The IRIS trial involved 3,876 
non-diabetic patients with insulin resistance with prior stroke or TIA.  Active therapy with 
pioglitazone reduced the time to a composite cardiovascular outcome of fatal or nonfatal 
myocardial infarction and stroke (HR 0.74 [0.62-0.93] vs. placebo. The specific HR for 
stroke alone in IRIS was 0.82 (0.61-1.10.) using the original definition of stroke at the trial’s 
conception.  In a pre-specified analysis, however, using the updated 2013 consensus criteria 
for ischemic stroke, the HR was 0.75 (0.60-0.94) in favour of pioglitazone, interestingly 
precisely the same as that obtained for the entire observation period in cohort 1 and very 
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close to that in cohort 2. 
Two meta-analyses have reported a similar reduced relative risk of stroke for patients treated 
with pioglitazone to the PROactive study, perhaps not surprisingly, as both were numerically 
dominated by that trial. Lincoff and colleagues reported a relative risk of 0.80 (0.62-1.04)
19
 in 
patients with type 2 diabetes whereas Liao and colleagues reported 0.78 (0.60- 1.02)
20
 in 
studies that also included data from IRIS. 
The precise mechanism that could explain these results is not clear. It is known that, in 
addition to its impact on insulin sensitivity, pioglitazone affects other risk factors for 
cerebrovascular disease. In the IRIS trial, for example, the profile of a range of risk factors 
including blood glucose, blood pressure, certain lipids and the inflammatory marker, C-
reactive protein, were improved
12
. Similar observations have also been reported in other 
investigations.
9,21,22,
 There may also be direct salutary effects via activation of PPAR-γ on the 
vascular endothelium, thrombotic factors, as well as cellular elements involved in the 
development of atheroma.
23 
To provide comparable controls, we matched patients directly on a broad range of 
demographic, treatment and clinical characteristics. As a result, we were able to match 
approximately 50% (4,234 (55.9%) to the first control cohort and 3,604 (47.6%) to the 
second of our original pioglitazone pool, this reduced the power of the study especially for 
those outcomes related to occurrence of strokes such as mortality and length of stay and also 
risk of recurrent stroke.  Similar studies using routine data from different cohorts would be of 
interest to confirm the magnitude of our findings.  
We used two cohorts of control for this study. The purpose of this was to partly address 
issues of confounding by indication inherent in pharmaco-epidemiolgical studies. Control 
cohort-1 were patients who had their regimen changed at the same time as their control and 
thus to some extent were at a similar stage of the treatment pathway. However, it should be 
noted that for reasons of physician preference, contra-indication or other factors they were 
not prescribed pioglitazone, and thus confounding by indication may remain. For example, 
given the drug’s salt-retaining properties and contraindication in heart failure, patients with 
suspected left ventricular dysfunction (without diagnosed heart failure, which was an 
exclusion), who may have been an inherently higher risk for stroke, may have been 
prescribed other agents. 
Control cohort-2 were not constrained to being prescribed any additional therapy, i.e. 
changing regimen at the same time as the index case, but continued on the same treatment as 
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their respective case prior to the addition of pioglitazone. The direction of confounding by 
indication may therefore be considered to be ‘against’ the case group, in that their therapy 
was intensified possibly due to a perceived treatment failure or progression of disease. 
However, there is also the possibility that the intensification of treatment may proxy other 
elements such as closer monitoring or greater awareness of the patient and/or their physician. 
It should be noted that in the baseline characteristics of this group (Table 2), cases were more 
likely to be prescribed lipid lowering, anti-platelet and anti-hypertensive medication which 
may be indicative of potential differences between the management of these groups – some 
of which may not have be accounted for in our multivariable model. 
There are other limitations to this study. Patient ethnicity, known to impact on diabetes 
progression and outcome, is not systematically recorded within the CPRD dataset and so was 
excluded as a potential confounding variable. However, we do not believe that there would 
be significant differences between prescription rates of pioglitazone by ethnic group. 
Furthermore, exposure to the regimens can only be taken as an intention-to-treat on the part 
of the prescriber.  From the data source it is not possible to determine whether the patient 
collected the prescription of whether they took the treatment at the prescribed dosage. Due to 
different side-effects between different therapies it is possible that adherence rates between 
treatment groups may have been different.  
Unlike a trial situation, real-world observational studies may not contain key information 
recorded at baseline or at subsequent follow-up periods. As such, missing data is inevitable. It 
is likely that data would not be missing at random but will instead reflect the number of 
health contacts a person has, and therefore can be considered a proxy for morbidity. Within 
this study we categorized key variables with ‘missing’ included as a category in order to 
maximize patient numbers but may have lost some of the granularity of this data. It is 
therefore important to consider this in the interpretation of results. 
The quality of coding of outcomes in routine data has been questioned but within CPRD and 
HES the data quality is considered reasonably robust.
24,25,26
 Whilst some events may be 
misdiagnosed, incorrectly transcribed or omitted, we do not consider it likely that there would 
be a differential bias in error rates between the cohorts and thus whilst the absolute number of 
events may be questioned, the relative difference between treatment arms should persist. 
 
Conclusion 
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In conclusion, this study found a significant reduction in incident stroke for patients treated 
with pioglitazone compared with other glucose lowering strategies, matched to controls in 
two analysis cohorts and over two follow-up periods. There was no clear effect, however, on 
stroke mortality, recurrent stroke or hospital length of stay.  These data support the findings 
from PROactive in patients with type 2 diabetes and established macrovascular disease and 
also from IRIS in patients with insulin resistance but without diabetes.  Further study is 
warranted into the beneficial effects of this insulin sensitizing drug in patients with or at risk 
for cerebrovascular disease. As a result of the consistency of the findings across randomized 
trials and observational data sets, guideline committees should now consider a 
recommendation to use pioglitazone, barring contraindications, in secondary stroke 
prevention, at least in patients with type 2 diabetes. 
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Table 1. 
Baseline characteristics of patients initiated with pioglitazone and matched controls – control 
cohort-1 
 
Case Control p-value 
Number 4,234 4,234 
Gender*  1,665 (39.3%) 1,665 (39.3%) 1.000 
Age, years**  61.4 (10.8) 61.5 (10.8) 0.837 
Follow-up on therapy, years** 2.4 (2.1) 2.5 (2.3) 0.025 
Follow-up to end of study, years** 5.5 (2.9) 5.1 (2.8) <0.001 
Charlson index ** 2.1 (1.4) 2.1 (1.4) 0.667 
Primary care contacts in prior year ** 10.4 (8.3) 10.7 (9.2) 0.145 
Duration of diabetes, years ** 4.4 (3.1) 4.4 (3.1) 0.607 
Body Mass Index, ** 32.2 (6.1) 31.7 (6.3) 0.001 
HbA1c, DCCT, % ** 7.1 (12.6) 7.0 (12.6) 0.811 
Systolic blood pressure, mmHg ** 136.1 (14.7) 135.7 (15.3) 0.254 
Total cholesterol, mmol/L ** 4.4 (1.1) 4.4 (1.1) 0.045 
Serum creatinine umol/L ** 85.4 (24.1) 85.1 (25.7) 0.551 
Lipid lowering therapy * 3,459 (81.7%) 3294 (77.8%) <0.001 
Anti-hypertensives * 3,056 (72.2%) 3055 (72.2%) 1.000 
Anti-platelet therapy * 1,889 (44.6%) 1853 (43.8%) 0.444 
History of prior stroke * 86 (2.0%) 86 (2.0%) 1.000 
History of atrial fibrillation * 145 (3.4%) 185 (4.4%) 0.028 
Smoking history 0.328 
   Never smoked (%) 1,656 (39.1%) 1697 (39.3%) 
   Ex-smoker (%) 1,892 (44.7%) 1823 (39.3%) 
   Current smoker (%) 686 (16.2%) 711 (39.3%) 
* n (%), ** mean (standard deviation). 
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Table 2. 
Baseline characteristics of patients initiated with pioglitazone and matched controls – control 
cohort-2 
 
Case Control p-value 
Number 3,604 3,604 
Gender*  1367 (37.9%) 1367 (37.9%) 1.000 
Age, years**  61.0 (10.9) 61.0 (11.0) 0.828 
Follow-up on therapy, years** 2.4 (2.1) 2.7 (2.4) <0.001 
Follow-up to end of study, years** 5.6 (2.9) 5.0 (3.0) <0.001 
Charlson index ** 2.1 (1.4) 2.1 (1.4) 0.564 
Primary care contacts in prior year ** 10.4 (8.2) 9.6 (7.6) <0.001 
Duration of diabetes, years ** 4.4 (3.1) 4.4 (3.1) 0.690 
Body Mass Index, ** 32.3 (6.1) 31.6 (6.2) <0.001 
HbA1c, DCCT, % ** 6.8 (13.5) 6.6 (13.5) 0.427 
Systolic blood pressure, mmHg ** 135.7 (14.7) 136.1 (14.9) 0.220 
Total cholesterol, mmol/L ** 4.3 (1.0) 4.5 (1.1) <0.001 
Serum creatinine umol/L ** 84.7 (22.6) 84.5 (22.1) 0.690 
Lipid lowering therapy * 2981 (82.7%) 2702 (75.0%) <0.001 
Anti-hypertensives * 2621 (72.7%) 2502 (69.4%) 0.002 
Anti-platelet therapy * 1641 (45.5%) 1480 (41.1%) <0.001 
History of prior stroke * 85 (2.4%) 85 (2.4%) 1.000 
History of atrial fibrillation * 118 (3.3%) 156 (4.3%) 0.023 
Smoking history <0.001 
   Never smoked (%) 1392 (38.6%) 1536 (42.6%) 
   Ex-smoker (%) 1630 (45.2%) 1442 (40.0%) 
   Current smoker (%) 582 (16.1%) 625 (17.3%) 
* n (%), ** mean (standard deviation). 
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Table 3 
Number, crude rate and crude relative risk for incident stroke for patients initiated with 
pioglitazone and matched controls. 
Case Control Crude relative risk (95% CI) 
Control cohort-1 Events Rate* Events  Rate* 
  On-treatment 50 5.0 79 7.5 0.662 (0.462-0.941) 
  Until end of follow up 174 7.5 211 9.9 0.761 (0.622-0.930) 
Control cohort-2       
  On-treatment 34 3.9 69 7.0 0.551 (0.362-0.827) 
  Until end of follow up 144 7.2 152 8.5 0.844 (0.672-1.060) 
* Rate per 1,000 person years. 
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Number and proportion of stroke events resulting in 30-day mortality for patients initiated with pioglitazone and matched controls. 
 
Cases Controls Odds ratio p-value* 
 n Deaths (%) n Deaths (%)   
Control cohort-1        
  On-treatment 50 6 (12.0%) 79 10 (12.7%) 
0.891 (0.286-2.776) 
 
0.843 
  Until end of follow up 
174 18 (10.3%) 211 26 (12.3%) 
0.744 (0.387-1.43) 
 
0.375 
Control cohort-2  
  On-treatment 
34 3 (8.8%) 69 7 (10.1%) 
0.931 (0.215-4.025) 
 
0.924 
  Until end of follow up 
144 16 (11.1%) 152 18 (11.8%) 
0.912 (0.441-1.884) 
 
0.803 
 
*Adjusted for age, gender, Charlson index 
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Table 5 
Destination on discharge and associated length of stay for patients initiated with pioglitazone 
and matched controls. 
  Case Control   
  
Number 
Median LOS 
(IQR) 
Number 
Median LOS 
(IQR)   
Cohort 1 
On-treatment 
Usual residence 31 3 (1-8) 51 3 (2-11) 0.645 
Death 5 5 (1-11) 9 3 (3-6) 0.687 
Nursing home 1 42 (42-42) 1 45 (45-45) 1.000 
Transfer to acute unit 5 3 (3-30) 10 17 (7-21) 0.713 
Other 0 1 19 (19-19) **** 
All admissions 42 4 (1-11) 72 5 (2-15) 0.419 
End of follow up 
Usual residence 113 6 (2-15) 128 3 (2-11) 0.196 
Death 20 13 (5-51) 21 5 (3-25) 0.120 
Nursing home 2 56 (42-69) 1 45 (45-45) 1.000 
Transfer 17 9 (5-29) 30 21 (7-41) 0.090 
Other 0 15 (10-19) **** 
All admissions 152 7 (2-20) 182 6.0 (2-17) 0.417 
Cohort 2 
On-treatment 
Usual residence 20 3 (1-8) 42 7 (3-18) 0.008 
Death 3 5 (1-14) 7 7 (6-41) 0.209 
Nursing home 1 91 (91-91) **** 
Transfer to acute unit 4 17 (2-45) 5 13  (8-17) 0.624 
Other 1 3 (3-3) 2 63 (14-111) 0.221 
All admissions 28 3 (1-8) 57 8 (5-20) 0.002 
End of follow up 
Usual residence 85 5 (1-15) 97 6 (2-11) 0.485 
Death 19 14 (5-51) 15 6 (4-21) 0.211 
Nursing home 1 69 (69-69) 2 72 (53-91) 1.000 
Transfer 17 11 (6-32) 16 15 (8-36) 0.929 
Other 1 3 (3-3) 2 63 (14-111) 0.221 
All admissions 123 6 (2-20) 132 7 (3-16) 0.941 
*Adjusted for age and gender 
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